1. VKA Reversal and LVADs

3. Program Goals

4. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

5. Introduction

6. Risks of LVAD Use

7. Case Study 72-Year-Old Man With a Minor Bleed

8. Management Considerations Minor Bleed With Supratherapeutic INR

9. Case Study (cont) Development of an Intermediate GI Bleed

10. Management Considerations (cont) Intermediate GI Bleed With LVAD

11. FFP vs PCC

12. Is There a Role for FFP in VKA Reversal in Patients With LVAD and Bleeding?

13. Types of PCCs

14. 4-Factor PCC and Risk of Thrombosis in Continuous Flow LVAD

15. Reversing VKA With Vitamin K in Patients With LVAD

16. Case Study (cont) Development of a Critical Bleed (ICH)

17. Management Considerations (cont) Critical Bleed (ICH) With LVAD

18. Case Conclusion Preparation for Heart Transplant

19. Management Considerations (cont) Preparation for Heart Transplant

20. Summary

21. Abbreviations

22. Abbreviations (cont)